19
NOV
2018
Updated Interim Data from Phase 3 Trial of DCVax®-L for Glioblastoma
Comments : Off
Presented at Society for Neuro-Oncology Conference Data Continuing to Mature, Particularly Regarding Long Tail of Survival Curve BETHESDA, Md., November 19, 2018 – Northwest Biotherapeutics (OTCQB: NWBO) — (“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that updated blinded interim data from the Phase 3 trial of DCVax®-L for Glioblastoma brain cancer were presented... Read More